Stock Detail
XOMA LTD
Sector: Biotechnology
Latest Quote @ Wed Jun 6 06:22:05 (15 min delayed)
| N/A |
N/A |
$3.84 |
-0.01 |
-0.26% |
|
Last Day's Data
| $3.84 |
$3.98 |
$0.00 |
0.00% |
0.00 |
$3.85 |
| $3.86 |
$3.81 |
711,224.00 |
318.31M |
664,684.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 4.05 |
3.95 |
3.88 |
3.78 |
3.71 |
Stock Profile
XOMA, Ltd., a biopharmaceutical company, engages in the development and manufacture of antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer, and infectious diseases. The company's proprietary and collaborative product development programs include RAPTIVA, a humanized therapeutic monoclonal antibody, for the treatment of adults for moderate to severe plaque psoriasis; CHIR-12.12, an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies; and NEUPREX, a Phase II clinical trial product, IV formulation of rBPI21, a modified recombinant fragment of bactericidal/permeability-increasing protein for multiple anti-infective and antiendotoxin indications. Its development products also comprise MLN2222, a Phase II clinical trial product, a complement inhibitor under development to reduce the incidence of complications in patients undergoing surgical procedures involving the use of cardiopulmonary bypass; Gastrin, a preclinical antigastrin antibody, for Gastric cancers; ING-1, a Phase I clinical trial product, Human Engineered antibody to Ep-CAM for Adenocarcinomas; and XMP.629, a topical formulation of BPI derived antimicrobial peptide fro acne. XOMA, Ltd. also licenses its proprietary technologies relating to bacterial expression of recombinant pharmaceutical products, as well as its Human Engineering technology that allows modification of any nonhuman monoclonal antibody to reduce or eliminate detectable immunogenicity in humans to biotechnology and pharmaceutical companies. It has collaboration and license agreements with Genentech, Inc.; Chiron Corporation; Zephyr Sciences, Inc.; Millennium Pharmaceuticals, Inc.; Aphton Corporation; Merck & Co., Inc.; Lexicon Genetics Incorporated; Cubist Pharmaceuticals, Inc.; and Triton BioSystems, Inc. The company was founded by Patrick J. Scannon. XOMA, Ltd. was incorporated in 1981 and is headquartered in Berkeley, California.
